Patents by Inventor Carlos Manuel Martinez Viturro

Carlos Manuel Martinez Viturro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME
    Publication number: 20230203044
    Abstract: The invention relates to novel compounds for use as in-hibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
    Type: Application
    Filed: April 15, 2021
    Publication date: June 29, 2023
    Inventors: Daniel OEHLRICH, Michiel Luc Maria VAN GOOL, Nina VAN OPDENBOSCH, Mohamed LAMKANFI, Josep LLAVERIA CROS, Carlos Manuel MARTINEZ VITURRO, Dries VAN ROMPAEY
  • PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY
    Publication number: 20230183248
    Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I), Formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
    Type: Application
    Filed: April 15, 2021
    Publication date: June 15, 2023
    Inventors: Daniel OEHLRICH, Michiel Luc Maria VAN GOOL, Nina VAN OPDENBOSCH, Mohamed LAMKANFI, Joseph Elisabeth LEENAERTS, Carlos Manuel MARTINEZ VITURRO, Michael Eric MURATORE
  • OGA INHIBITOR COMPOUNDS
    Publication number: 20210300943
    Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
    Type: Application
    Filed: June 20, 2019
    Publication date: September 30, 2021
    Inventors: José Manuel Bartolomé-Nebreda, Andrés Avellno Trabanco-Suárez, Carlos Manuel Martinez-Viturro, Francisca Deigado-Jiménez, Susana Coride-Ceide, Juan Antonio Vega Ramiro
  • OGA INHIBITOR COMPOUNDS
    Publication number: 20210277015
    Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
    Type: Application
    Filed: June 20, 2019
    Publication date: September 9, 2021
    Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Carlos Manuel Martinez-Viturro, Francisca Delgado-Jiménez, Susana Conde-Ceide, Juan Antonio Vega Ramiro
  • OGA INHIBITOR COMPOUNDS
    Publication number: 20210261527
    Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
    Type: Application
    Filed: June 20, 2019
    Publication date: August 26, 2021
    Inventors: José Manuel Bartolomé-Nebreda, Andres Avellno Trabanco-Suarez, Carlos Manuel Martinez-Viturro
  • MONOCYCLIC OGA INHIBITOR COMPOUNDS
    Publication number: 20200079766
    Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
    Type: Application
    Filed: December 15, 2017
    Publication date: March 12, 2020
    Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Carlos Manuel Martinez Viturro, Gary John Tresadem, Manuel Jesús Alcázar-Vaca, Wei Zhang, Gang Chen
  • OGA INHIBITOR COMPOUNDS
    Publication number: 20200048267
    Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
    Type: Application
    Filed: February 6, 2018
    Publication date: February 13, 2020
    Applicant: Janssen Pharmaceutica NV
    Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Carlos Manuel Martinez Viturro
  • BICYCLIC OGA INHIBITOR COMPOUNDS
    Publication number: 20190359609
    Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
    Type: Application
    Filed: December 15, 2017
    Publication date: November 28, 2019
    Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Carlos Manuel Martinez Viturro, Gary John Tresadern, Manuel Jesús Alcázar-Vaca